Delivery Order SPE2DB24D2013-SPE2DB25FCJXA
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,361.80 to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Ozempic (semaglutide) 0.25–0.5 mg/dose pens in 3 mL formulations. This competitive award uses firm fixed pricing with no set-aside designation and is scheduled for completion by August 12, 2025. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $5,292.97 to AmerisourceBergen Drug Corp for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pens in 3ml configurations. This competitively awarded, firm fixed-price contract was issued on July 22, 2025, with an ultimate completion date of July 23, 2025, and represents a child order under a larger contract vehicle. The award is categorized as a delivery order rather than a standalone contract, indicating it was placed against...
- The Defense Logistics Agency awarded a delivery order valued at $9,392.34 to AmerisourceBergen Drug Corp for the supply of Ozempic (semaglutide) 0.25–0.5 mg/dose pens in 3 mL formulations. This competitively awarded, firm fixed-price contract was issued on July 23, 2025, with an ultimate completion date of July 24, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order carries no set-aside designation, reflecting the open...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Ozempic (semaglutide) 0.25–0.5 mg/dose pens in 3 mL formulations. This competitively awarded, non-set-aside delivery order carries a ceiling value of $32,930.62 under firm fixed-price terms, with an ultimate completion date of August 19, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $27,396.14 delivery order to AmerisourceBergen Drug Corp for Ozempic 0.25-0.5 mg/dose pens (3ml) on July 18, 2025, with an ultimate completion date of July 21, 2025. This competitively awarded contract utilizes firm fixed pricing with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $5,826.53 to AmerisourceBergen Drug Corp for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pens in 3 mL formulations. The contract is firm fixed price with no set-aside designation and was awarded on July 28, 2025, with an ultimate completion date of July 29, 2025. Performance will be executed at the awardee's facility in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's broader...
- The Defense Logistics Agency awarded a delivery order valued at $17,858.37 to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL). The contract utilizes firm fixed pricing and carries an ultimate completion date of August 4, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded without set-aside designation, reflecting AmerisourceBergen's...
- The Defense Logistics Agency awarded a $13,541.70 delivery order to AmerisourceBergen Drug Corp for Ozempic (0.25-0.5 mg/dose pen, 3ml) on July 30, 2025, with a completion date of July 31, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $18,198.96 to AmerisourceBergen Drug Corp for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pens in 3mL vials. The contract was competitively awarded with firm fixed pricing and is scheduled for completion by August 13, 2025. AmerisourceBergen will fulfill this order from its corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $15,411.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pen 3ml formulations. The contract was competitively awarded without a set-aside designation and is scheduled for completion by July 24, 2025. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance. This delivery order is issued under the company's broader Indefinite Delivery...
- SPE2DB24D2013Indefinite Delivery Contract
- SPE2DB24D2013-SPE2DB25FCJXADelivery Order
The Defense Logistics Agency awarded a $35,602.74 delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pens in 3 mL format. This is a firm fixed-price, competitively awarded contract with no set-aside designation, with a performance location in Conshohocken, Pennsylvania and an ultimate completion date of August 14, 2025. The delivery order was issued on August 13, 2025, as a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. This award represents a routine pharmaceutical procurement through AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999 million through December 2026. As a primary pharmaceutical distributor for federal medical supply chains, AmerisourceBergen regularly fulfills delivery orders for brand-name and generic medications supporting military and veteran healthcare systems. The Ozempic procurement exemplifies the company's role in supplying specialty diabetes medications and other therapeutic pharmaceuticals to support Defense Health Agency operations and broader federal healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $35.6k | 8/13/25 |